Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Philippe Soubeyran

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5876-3217; OpenAlex author ID A5074609153. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
38
Papers, trials and grants by year

2018: 3 papers · 2019: 3 papers · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 13

  1. Single-cell transcriptomic profiling of patient-derived pancreatic ductal adenocarcinoma primary cell cultures. Co-author DOI 10.1038/s41597-026-07380-3↗
  2. A comprehensive proteomic dataset of secretomes from primary pancreatic cancer cell cultures. Last author DOI 10.1038/s41597-026-07902-z↗
  3. E-Cadherin Is a Structuring Component of Invadopodia in Pancreatic Cancer. Co-author DOI 10.1111/jcmm.70608↗
  4. Pancreatic ductal adenocarcinoma ubiquitination profiling reveals specific prognostic and theranostic markers. Last author DOI 10.1016/j.ebiom.2023.104634↗
  5. Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. Co-author DOI 10.1016/j.ebiom.2021.103332↗
  6. TNF-α induces endothelial-mesenchymal transition promoting stromal development of pancreatic adenocarcinoma. First author DOI 10.1038/s41419-021-03920-4↗
  7. MiR-93 is related to poor prognosis in pancreatic cancer and promotes tumor progression by targeting microtubule dynamics. Co-author DOI 10.1038/s41389-020-0227-y↗
  8. PML hyposumoylation is responsible for the resistance of pancreatic cancer. Last author DOI 10.1096/fj.201901091r↗
  9. Upcoming Revolutionary Paths in Preclinical Modeling of Pancreatic Adenocarcinoma. First author DOI 10.3389/fonc.2019.01443↗
  10. Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cells8111453↗
  11. Pancreatic cancer chemo-resistance is driven by tumor phenotype rather than tumor genotype. Last author DOI 10.1016/j.heliyon.2018.e01055↗
  12. Chloroquine plays a cell-dependent role in the response to treatment of pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.25745↗
  13. Ribonuclease MCPiP1 contributes to the loss of micro-RNA-200 family members in pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.26310↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Juan Iovanna · 13 shared papers, 2018–2026 · strength 1.97
  2. Nelson Dusetti · 6 shared papers, 2019–2026 · strength 1.18
  3. Julie Roques · 6 shared papers, 2019–2026 · strength 1.07
  4. Nicolas Alejandro Fraunhoffer · 4 shared papers, 2021–2026 · strength 0.86
  5. Odile Gayet · 5 shared papers, 2018–2026 · strength 0.73
  6. Brice Chanez · 2 shared papers, 2026 · strength 0.58
  7. Mirna Swayden · 4 shared papers, 2018–2019 · strength 0.47
  8. Yolande Berthois · 3 shared papers, 2018–2023 · strength 0.33
  9. Aurélie Dobric · 2 shared papers, 2018–2025 · strength 0.32
  10. Vladimir Chocoloff · 1 shared paper, 2026 · strength 0.30
  11. Abdessamad El Kaoutari · 2 shared papers, 2021–2023 · strength 0.29
  12. Frederic André · 1 shared paper, 2025 · strength 0.24
  13. Raul A. Urrutia · 2 shared papers, 2019–2021 · strength 0.21
  14. Gwen Alyce Lomberk · 2 shared papers, 2019–2021 · strength 0.21
  15. Roselyne Tournaire · 1 shared paper, 2021 · strength 0.13
  16. Marjorie Adjuto Saccone · 1 shared paper, 2021 · strength 0.13
  17. Owen Hoare · 1 shared paper, 2021 · strength 0.12
  18. Maria Rovira-Rigau · 1 shared paper, 2020 · strength 0.11
  19. Elena Vila-Navarro · 1 shared paper, 2020 · strength 0.11
  20. Elena Fernández-Castañer · 1 shared paper, 2020 · strength 0.11
  21. María Vila-Casadesús · 1 shared paper, 2020 · strength 0.11
  22. Cristina Fillat · 1 shared paper, 2020 · strength 0.11
  23. Giulia Raimondi · 1 shared paper, 2020 · strength 0.11
  24. Meritxell Gironella · 1 shared paper, 2020 · strength 0.11
  25. Daniele Fanale · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.